{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:55Z","timestamp":1793146675895,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40265-023-01834-3","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T10:45:10Z","timestamp":1674125110000},"page":"265-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Mirvetuximab Soravtansine: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"issue":"12","key":"1834_CR1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","volume":"18","author":"JF Ponte","year":"2016","unstructured":"Ponte JF, Ab O, Lanieri L, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in Ovarian cancer models. Neoplasia. 2016;18(12):775\u201384.","journal-title":"Neoplasia"},{"issue":"2","key":"1834_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FR alpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR alpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147(2):402\u20137.","journal-title":"Gynecol Oncol"},{"key":"1834_CR3","unstructured":"Food & Drug Administration. FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer [media release]. 14 Nov 2022. https:\/\/www.fda.gov\/"},{"key":"1834_CR4","unstructured":"ImmunoGen. ElahereTM (mirvetuximab soravtansine-gynx) injection, for intravenous use. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761310s000lbl.pdf. Accessed 28 Nov 2022."},{"issue":"2","key":"1834_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10637-020-00995-2","volume":"39","author":"C Yam","year":"2021","unstructured":"Yam C, Rauch GM, Rahman T, et al. A phase II study of mirvetuximab soravtansine in triple-negative breast cancer. Invest New Drugs. 2021;39(2):509\u201315.","journal-title":"Invest New Drugs"},{"key":"1834_CR6","unstructured":"National Comprehensive Cancer Network. NCCN receives $2-million funding commitment from ImmunoGen Inc. to study mirvetuximab soravtansine for folate receptor alpha-positive cancers [media release]. 18 May 2015. http:\/\/www.nccn.org."},{"key":"1834_CR7","unstructured":"National Comprehensive Cancer Network. NCCN awards research grants to eight investigators to support clinical and pre-clinical studies of mirvetuximab soravtansine in various cancers [media release]. 7 Jun 2016. http:\/\/www.nccn.org."},{"key":"1834_CR8","unstructured":"ImmunoGen, Merck. ImmunoGen and Merck establish collaboration for clinical evaluation of mirvetuximab soravtansine in combination with Keytruda\u00ae(pembrolizumab) for the treatment of ovarian cancer [media release]. 4 Feb 2016. http:\/\/www.immunogen.com."},{"key":"1834_CR9","unstructured":"ImmunoGen, Huadong Medicine. ImmunoGen and Huadong Medicine announce strategic collaboration to develop and commercialize mirvetuximab soravtansine in Greater China [media release]. 20 Oct 2020. www.immunogen.com."},{"issue":"7","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a folate receptor-\u03b1 (FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors. Mol Cancer Ther. 2015;14(7):1605\u201313.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1834_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1535-7163.MCT-17-0930","volume":"17","author":"G Altwerger","year":"2018","unstructured":"Altwerger G, Bonazzoli E, Bellone S, et al. In vitro and In vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther. 2018;17(5):1003\u201311.","journal-title":"Mol Cancer Ther"},{"issue":"16 Suppl","key":"1834_CR12","first-page":"2","volume":"80","author":"A Chelariu-Raicu","year":"2020","unstructured":"Chelariu-Raicu A, Stur E, Ivan C, et al. Biological effects of a FR\u03b1-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer [abstract no 1237]. Cancer Res. 2020;80(16 Suppl):2.","journal-title":"Cancer Res"},{"issue":"Suppl 7","key":"1834_CR13","doi-asserted-by":"publisher","first-page":"S822","DOI":"10.1016\/j.annonc.2022.07.733","volume":"33","author":"KN Moore","year":"2022","unstructured":"Moore KN, Lorusso D, Oaknin A, et al. Population pharmacokinetic analysis of mirvetuximab soravtansine in patients with folate receptor \u03b1\u2013positive cancer [abstract no 605P]. Ann Oncol. 2022;33(Suppl 7):S822\u20133.","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"1834_CR14","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/S0090-8258(22)01297-5","volume":"166","author":"U Matulonis","year":"2022","unstructured":"Matulonis U, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study [abstract no LBA4]. Gynecol Oncol. 2022;166(Suppl 1):S50.","journal-title":"Gynecol Oncol"},{"issue":"16 Suppl","key":"1834_CR15","first-page":"1","volume":"40","author":"UA Matulonis","year":"2022","unstructured":"Matulonis UA, Oaknin A, Pignata S, et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR\u03b1) expression: characterization of antitumor activity in the SORAYA study [abstract no 5512]. J Clin Oncol. 2022;40(16 Suppl):1.","journal-title":"J Clin Oncol"},{"key":"1834_CR16","doi-asserted-by":"crossref","unstructured":"Coleman RL, Lorusso D, Oaknin A, et al. Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the SORAYA study [abstract no. 376]. Int J Gynecol Cancer. 2022;32(Suppl 3).","DOI":"10.1136\/ijgc-2022-igcs.30"},{"issue":"6","key":"1834_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757\u201365.","journal-title":"Ann Oncol"},{"issue":"Suppl 7","key":"1834_CR18","doi-asserted-by":"publisher","first-page":"S790","DOI":"10.1016\/j.annonc.2022.07.660","volume":"33","author":"KN Moore","year":"2022","unstructured":"Moore KN, Oza AM, Colombo N, et al. Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011) [abstract no 532P]. Ann Oncol. 2022;33(Suppl 7):S790\u20131.","journal-title":"Ann Oncol"},{"key":"1834_CR19","doi-asserted-by":"crossref","unstructured":"Moore K, Oza A, Colombo N, et al. FORWARD I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) [abstract no 992O]. Ann Oncol 2019;30 (Suppl 5):v403.","DOI":"10.1093\/annonc\/mdz250"},{"issue":"Suppl 2","key":"1834_CR20","first-page":"A2251","volume":"32","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Lorusso D, Oza A, et al. Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alphapositive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine [abstract no. 2022-RA-660-ESGO and poster presentation]. Int J Gynecol Cancer. 2022;32(Suppl 2):A2251\u20132.","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 7","key":"1834_CR21","doi-asserted-by":"publisher","first-page":"S817","DOI":"10.1016\/j.annonc.2022.07.720","volume":"33","author":"UA Matulonis","year":"2022","unstructured":"Matulonis UA, Moore KN, Lorusso D, et al. Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor [alpha] (FR[alpha])-positive cancer [abstract no 592P]. Ann Oncol. 2022;33(Suppl 7):S817.","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"1834_CR22","first-page":"3","volume":"39","author":"DM O'Malley","year":"2021","unstructured":"O\u2019Malley DM, Oaknin A, Matulonis UA, et al. Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis [abstract no 5504]. J Clin Oncol. 2021;39(15 Suppl):3.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"1834_CR23","doi-asserted-by":"publisher","first-page":"S626","DOI":"10.1016\/j.annonc.2020.08.972","volume":"31","author":"DM O'Malley","year":"2020","unstructured":"O\u2019Malley DM, Richardson DL, Vergote IB, et al. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer [abstract no. 833P]. Ann Oncol. 2020;31(Suppl 4):S626\u20137.","journal-title":"Ann Oncol"},{"issue":"2","key":"1834_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","volume":"157","author":"DM O'Malley","year":"2020","unstructured":"O\u2019Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379\u201385.","journal-title":"Gynecol Oncol"},{"key":"1834_CR25","unstructured":"ImmunoGen. ImmunoGen announces positive findings from the FORWARD II study of mirvetuximab soravtansine combination regimens with Avastin\u00ae and carboplatin in ovarian cancer [media release]. 16 May 2018. http:\/\/www.immunogen.com."},{"key":"1834_CR26","doi-asserted-by":"crossref","unstructured":"Moore, KN, O'Malley DM, Vergote I, et al. Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis [abstract no 499]. Int J Gynecol Cancer. 2022;32(Suppl 3):A33\u20134.","DOI":"10.1136\/ijgc-2022-igcs.62"},{"issue":"Suppl 8","key":"1834_CR27","doi-asserted-by":"publisher","first-page":"viii339","DOI":"10.1093\/annonc\/mdy285.157","volume":"29","author":"U Matulonis","year":"2018","unstructured":"Matulonis U, Moore K, Martin L, et al. Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): initial results of an expansion cohort from FORWARD II, a phase Ib study [abstract no 949P]. Ann Oncol. 2018;29(Suppl 8):viii339.","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"1834_CR28","first-page":"16","volume":"32","author":"D O'Malley","year":"2022","unstructured":"O\u2019Malley D, Oaknin A, Matulonis U, et al. Mirvetuximab soravtansine and bevacizumab in folate receptor \u03b1lpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab [abstract no 496]. Int J Gynecol Cancer. 2022;32(Suppl 3):16\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 1","key":"1834_CR29","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/S0090-8258(21)00771-X","volume":"162","author":"F Backes","year":"2021","unstructured":"Backes F, Wei L, Copeland L, et al. Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer [abstract no 120]. Gynecol Oncol. 2021;162(Suppl 1):S68\u20139.","journal-title":"Gynecol Oncol"},{"key":"1834_CR30","doi-asserted-by":"crossref","unstructured":"Cristea MC, Ruel NH, Frankel PH, et al. A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (pts) with selected FR alpha-positive solid tumors: results in the ovarian cancer (EC) cohort [abstract no. 5542]. J Clin Oncol. 2021;39(15 Suppl).","DOI":"10.1200\/JCO.2021.39.15_suppl.5542"},{"issue":"16","key":"1834_CR31","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1002\/cncr.30736","volume":"123","author":"KN Moore","year":"2017","unstructured":"Moore KN, Borghaei H, O\u2019Malley DM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123(16):3080\u20137.","journal-title":"Cancer"},{"issue":"10","key":"1834_CR32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, Martin LP, O\u2019Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35(10):1112\u20138.","journal-title":"J Clin Oncol"},{"key":"1834_CR33","unstructured":"ImmunoGen. ImmunoGen announces new clinical data with mirvetuximab soravtansine in ovarian cancer to be presented at 2017 ASCO annual meeting [media release]. 18 May 2017. http:\/\/www.immunogen.com."},{"issue":"16 Suppl","key":"1834_CR34","first-page":"1","volume":"40","author":"KN Moore","year":"2022","unstructured":"Moore KN, Lorusso D, Oaknin A, et al. Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor \u03b1 (FR\u03b1)-positive recurrent ovarian cancer: phase 1 and 3 clinical trials [abstract no 5574]. J Clin Oncol. 2022;40(16 Suppl):1.","journal-title":"J Clin Oncol"},{"key":"1834_CR35","unstructured":"Roche. Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for Elahere [media release]. 14 Nov 2022. http:\/\/www.roche.com."},{"key":"1834_CR36","unstructured":"Roche. VENTANA FOLR1 (FOLR1-2.1) RxDx Assay label. 2022. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf22\/P220006C.pdf. Accessed 30 Dec 2022."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01834-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01834-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:29:58Z","timestamp":1676428198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01834-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01834-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"19 January 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}